Cite
HARVARD Citation
Zhang, H. et al. (2022). A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia. Blood science. 4 (3), pp. 161-163. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zhang, H. et al. (2022). A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia. Blood science. 4 (3), pp. 161-163. [Online].